Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1995 1
1997 2
1998 1
1999 2
2000 2
2001 5
2002 2
2003 2
2006 2
2007 4
2008 3
2009 2
2010 4
2011 2
2014 2
2015 4
2016 4
2017 2
2018 1
2020 4
2021 1
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

49 results
Results by year
Filters applied: . Clear all
Page 1
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy.
Mayoux M, Roller A, Pulko V, Sammicheli S, Chen S, Sum E, Jost C, Fransen MF, Buser RB, Kowanetz M, Rommel K, Matos I, Colombetti S, Belousov A, Karanikas V, Ossendorp F, Hegde PS, Chen DS, Umana P, Perro M, Klein C, Xu W. Mayoux M, et al. Among authors: karanikas v. Sci Transl Med. 2020 Mar 11;12(534):eaav7431. doi: 10.1126/scitranslmed.aav7431. Sci Transl Med. 2020. PMID: 32161104
A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade.
Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S, Kiialainen A, Hanhart J, Schill C, Hess C, Savic Prince S, Wiese M, Lardinois D, Ho PC, Klein C, Karanikas V, Mertz KD, Schumacher TN, Zippelius A. Thommen DS, et al. Among authors: karanikas v. Nat Med. 2018 Jul;24(7):994-1004. doi: 10.1038/s41591-018-0057-z. Epub 2018 Jun 11. Nat Med. 2018. PMID: 29892065 Free PMC article.
A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.
Bacac M, Fauti T, Sam J, Colombetti S, Weinzierl T, Ouaret D, Bodmer W, Lehmann S, Hofer T, Hosse RJ, Moessner E, Ast O, Bruenker P, Grau-Richards S, Schaller T, Seidl A, Gerdes C, Perro M, Nicolini V, Steinhoff N, Dudal S, Neumann S, von Hirschheydt T, Jaeger C, Saro J, Karanikas V, Klein C, Umaña P. Bacac M, et al. Among authors: karanikas v. Clin Cancer Res. 2016 Jul 1;22(13):3286-97. doi: 10.1158/1078-0432.CCR-15-1696. Epub 2016 Feb 9. Clin Cancer Res. 2016. PMID: 26861458
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.
Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN, Kirkwood JM, Miller LD, Schendel DJ, Tanneau I, Wigginton JM, Butterfield LH. Gnjatic S, et al. Among authors: karanikas v. J Immunother Cancer. 2017 May 16;5:44. doi: 10.1186/s40425-017-0243-4. eCollection 2017. J Immunother Cancer. 2017. PMID: 28515944 Free PMC article. Review.
Immunotherapy biomarkers 2016: overcoming the barriers.
Gulley JL, Berzofsky JA, Butler MO, Cesano A, Fox BA, Gnjatic S, Janetzki S, Kalavar S, Karanikas V, Khleif SN, Kirsch I, Lee PP, Maccalli C, Maecker H, Schlom J, Seliger B, Siebert J, Stroncek DF, Thurin M, Yuan J, Butterfield LH. Gulley JL, et al. Among authors: karanikas v. J Immunother Cancer. 2017 Mar 21;5(1):29. doi: 10.1186/s40425-017-0225-6. J Immunother Cancer. 2017. PMID: 28653584 Free PMC article.
Immunoepigenetics: the unseen side of cancer immunoediting.
Germenis AE, Karanikas V. Germenis AE, et al. Among authors: karanikas v. Immunol Cell Biol. 2007 Jan;85(1):55-9. doi: 10.1038/sj.icb.7100006. Epub 2006 Nov 28. Immunol Cell Biol. 2007. PMID: 17130900 Review.
Tumor immune escape mediated by indoleamine 2,3-dioxygenase.
Zamanakou M, Germenis AE, Karanikas V. Zamanakou M, et al. Among authors: karanikas v. Immunol Lett. 2007 Aug 15;111(2):69-75. doi: 10.1016/j.imlet.2007.06.001. Epub 2007 Jul 2. Immunol Lett. 2007. PMID: 17644189 Review.
Determinants of cancer immunotherapy success.
Karanikas V, Germenis A. Karanikas V, et al. Expert Rev Vaccines. 2010 Dec;9(12):1363-6. doi: 10.1586/erv.10.138. Expert Rev Vaccines. 2010. PMID: 21105772 No abstract available.
49 results